Tag Archives: AI drug discovery

September 5, 2020
Broadcast

[Cheddar] Abraham Heifets, Co-founder & CEO of Atomwise joins Cheddar to discuss the company’s recent funding round and it’s coronavirus-related projects.

Read Article
August 27, 2020
In The News

[Nanalyze] Just a few weeks ago, Atomwise closed a $123 million Series B bringing their total funding so far to just over $174 million. The recent financing round includes new backing from two top-10 global insurance companies. Other notable investors include names like Monsanto, Tencent, Baidu Ventures, Khosla Ventures, Draper Associates, and OS Fund. The fresh […]

Read Article
August 25, 2020
In The News

[Analytics Insight] In recent years, the growing crops of startups that leverage artificial intelligence and other advanced technologies have ascended dramatically. As a result, the VC funding and investments in these startups are becoming historically strong year over year. Despite slow VC deals due to the COVID-19 crisis this year, the interest in AI funding is seeing a sustained […]

Read Article
August 19, 2020
In The News

[AiThority] Recently, a news report suggested that a team of AI scientists have made a belligerent effort to identify hundreds of new drugs as a potential COVID-19 therapy. COVID-19 is caused by the novel coronavirus, SAR COV-2, whose origins have been speculated to be a wet market in Wuhan in China. AI engineers and pharmaceutical companies are […]

Read Article
August 11, 2020
In The News

[Crunchbase] Atomwise, which is using artificial intelligence for small molecule drug discovery, received a cash infusion of $123 million in an oversubscribed Series B financing.

Read Article
August 11, 2020
In The News

[BioCentury] After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its

Read Article